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Abstract
Background: The elongation phase, like other steps of transcription by RNA Polymerase II, is subject to regulation.
The positive transcription elongation factor b (P-TEFb) complex allows for the transition of mRNA synthesis to the
productive elongation phase. P-TEFb contains Cdk9 (Cyclin-dependent kinase 9) as its catalytic subunit and is
regulated by its Cyclin partners, Cyclin T1 and Cyclin T2. The HIV-1 Tat transactivator protein enhances viral gene
expression by exclusively recruiting the Cdk9-Cyclin T1 P-TEFb complex to a RNA element in nascent viral
transcripts called TAR. The expression patterns of Cyclin T1 and Cyclin T2 in primary monocytes and CD4+ T cells
suggests that Cyclin T2 may be generally involved in expression of constitutively expressed genes in quiescent
cells, while Cyclin T1 may be involved in expression of genes up-regulated during macrophage differentiation, T
cell activation, and conditions of increased metabolic activity To investigate this issue, we wished to identify the
sets of genes whose levels are regulated by either Cyclin T2 or Cyclin T1.
Findings: We used shRNA lentiviral vectors to stably deplete either Cyclin T2 or Cyclin T1 in HeLa cells. Total RNA
extracted from these cells was subjected to cDNA microarray analysis. We found that 292 genes were down-
regulated by depletion of Cyclin T2 and 631 genes were down-regulated by depletion of Cyclin T1 compared to
cells transduced with a control lentivirus. Expression of 100 genes was commonly reduced in either knockdown.
Additionally, 111 and 287 genes were up-regulated when either Cyclin T2 or Cyclin T1 was depleted, respectively,
with 45 genes in common.
Conclusions: These results suggest that there is limited redundancy in genes regulated by Cyclin T1 or Cyclin T2.
Background
Positive transcription elongation factor b (P-TEFb) facili-
tates transition from abortive to productive mRNA elon-
gation by phosphorylating the carboxyl terminal domain
(CTD) of the large subunit of RNA Polymerase II (RNA
Pol II) and also the negative elongation factors NELF and
DSIF [1,2]. P-TEFb is essential for expression of most
RNA Pol II-transcribed genes and P-TEFb function
appears to be limiting for a large number of the non-
expressed set of genes in different cell types [3,4].
P-TEFb exists in two forms in cells, a core P-TEFb and a
snRNP complex. Core P-TEFb consists of Cdk9 as the
catalytic subunit, a Cyclin subunit either Cyclin T1 T2 or
K, and a protein known as Brd4 that is involved in direct-
ing core P-TEFb to active genes that are marked by
acetylated histones [5]. The snRNP form of P-TEFb is
catalytically inactive despite the presence of a Cyclin sub-
unit and Cdk9 that is phosphorylated in its T-loop [6]. In
addition to the core P-TEFb, the snRNP contains 7SK
snRNA, HEXIM (either HEXIM1 or HEXIM2), MePCE
(BCDIN3) and PIP7S (LARP7) proteins [5]. The precise
function of the snRNP form of P-TEFb is unknown but it
may serve to sequester excess Cdk9 and its Cyclin part-
ner in a complex that can be readily recruited to activate
RNA Pol II elongation [7].
The expression patterns of Cyclin T1 and Cyclin T2 dif-
fer in primary monocytes and CD4+ T cells. In general,
Cyclin T2 is expressed at a relatively high level in freshly
isolated monocytes and its level remains constant when the
cells are induced to undergo macrophage differentiation. In
contrast, Cyclin T1 is expressed at low levels in monocytes
and it is strongly up-regulated by a post-transcriptional
mechanism when the cells are induced to differentiate to
macrophages [8,9]. This up-regulation of Cyclin T1 protein
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expression appears to be required for the induction of a
large portion of cellular mRNAs that are regulated during
macrophage differentiation [10]. In resting primary CD4+
T cells, Cyclin T2 levels are also relatively high and change
little following T cell activation [11]. In contrast, Cyclin T1
levels are low in resting CD4+ T cells and are strongly
up-regulated following T cell activation by a post-transcrip-
tional mechanism [11-13]. This expression pattern of
Cyclin T2 and Cyclin T1 in quiescent vs. activated mono-
cytes and CD4+ T cells suggests that Cyclin T2 may be
generally involved in expression of constitutively expressed
genes in quiescent cells, while Cyclin T1 may be involved
in expression of genes up-regulated during macrophage
differentiation, T cell activation, and conditions of
increased metabolic activity [14].
HIV-1 replication requires the viral Tat protein for pro-
ductive RNA Pol II transcription of the integrated pro-
virus. Tat functions by recruiting P-TEFb to the TAR
RNA element that forms at the 5’ end of nascent viral
transcripts, where P-TEFb can phosphorylate the CTD,
NELF, and DSIF. Tat makes direct protein-protein contact
with Cyclin T1 and can therefore only utilize Cyclin
T1-containing P-TEFb complexes. Inhibition of P-TEFb
by siRNAs against Cyclin T1, a dominant negative-Cdk9
protein, or chemical inhibitors can inhibit HIV-1 replica-
tion in vitro [15-21]. It has been proposed that P-TEFb
inhibitors have therapeutic potential for treatment of HIV-
1 infection or cancer. A number of studies have also
shown that P-TEFb inhibitors have potential as che-
motherapeutic agents for some forms of cancer, such as
chronic lymphocytic leukemia [22,23] or hepatocellular
carcinoma [24]. A number of Cdk9 chemical inhibitors are
currently being evaluated in clinical trials for treatment of
various forms of cancer [25].
The effects of various P-TEFb inhibitors on cellular
growth and cytotoxicity have been described in a number
of studies. Stable expression of a dominant-negative Cdk9
protein has no observable effect on growth of a number of
cell lines, although it does sensitize the monocytic U937
cell line to apoptosis [18,19]. Selicilib and flavopiridol, che-
mical inhibitors of Cdk9, can inhibit HIV-1 replication in
cell lines at concentrations that are not cytotoxic [15,16].
Transient expression of siRNAs against Cyclin T1 or Cdk9
is able to inhibit HIV-1 replication without affecting the
growth rate of HeLa cells [17]. However, stable depletion
of Cdk9 using an shRNA vector that targets the 55 kDa
isoform of Cdk9 induces apoptosis in HeLa cells [26]. A
recent study generated a knock-out of the Cyclin T2 gene
in mice and showed that Cyclin T2 is essential for verte-
brate embryogenesis [27]. Transcriptional profiling in
murine embryonic stem (ES) cells depleted for either
Cyclin T2 or Cyclin T1 by transfected siRNAs identified a
limited set of Cyclin T2- and Cyclin T1-dependent genes
[27].
To further evaluate the effects of inhibition of P-TEFb
function on cellular physiology, in this study we have
used shRNA vectors to deplete Cyclin T1 and Cyclin T2
in HeLa cells where each of these P-TEFb subunits is
expressed at relatively high levels. The shRNA vectors
used here allow the stable depletion of target proteins,
unlike previous studies that used transfections of siR-
NAs against Cyclin T1 which display only a transient
depletion of the target proteins [17,27]. We found that
stable depletion of either Cyclin T1 or Cyclin T2 had no
effect on growth rates in HeLa cells. We carried out a
transcriptional profile analysis in Cyclin T1- and Cyclin
T2-depleted cells and identified cellular mRNAs whose
expression is dependent upon Cyclin T1, Cyclin T2, or
both Cyclin proteins.
Findings
The expression patterns of Cyclin T1 and Cyclin T2 in
primary monocytes and CD4+ T cells suggests that
Cyclin T2 may be generally involved in expression of
constitutively expressed genes in quiescent cells, while
Cyclin T1 may be involved in expression of genes up-
regulated during macrophage differentiation, T cell acti-
vation and conditions of increased metabolic activity
[9,11,12,14].
Depletion of Cyclin T2 or Cyclin T1 in HeLa cells does not
affect cell growth
We previously reported that the continuous expression
of siRNAs against Cyclin T1 from a shRNA lentiviral
vector displayed a stable knock-down and had no effect
on the growth rate of either Jurkat CD4+ T cells or
MM6 monocytic cells [10,14]. We wished to compare
the effects of stable depletions of Cyclin T1 and Cyclin
T2, and therefore constructed shRNA vectors that target
Cyclin T2. As a control shRNA vector, we used a
shRNA lentiviral vector termed MM (mismatch) which
contained a four nucleotide mismatch against the Cyclin
T1 mRNA that has previously been shown to have only
minimal effects on cellular mRNA expression levels
[10]. The target sequence against Cyclin T2 was selected
by a rational design strategy to a region common to
both isoforms, Cyclin T2a and T2b [28].
We first examined effects of Cyclin T2 and T1 deple-
tions. HeLa cell cultures were transduced with lentiviral
shRNA vectors against Cyclin T2, Cyclin T1 or the MM
control and at five days post-transduction, flow cytome-
try analysis showed that > 97% of cells in all three cul-
tures expressed the GFP marker protein (Figure 1A).
We note that there are two populations of GFP+ cells,
high- and low-expressors. The explanation for these two
populations is not known and we did not separate these
two populations in the transcriptional profiling
described below. The efficiency and specificity of Cyclin
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T2 depletion was examined by measuring the mRNA
levels of Cyclin T2 and Cyclin T1 using quantitative
real-time RT-PCR. The shRNA vector against Cyclin T2
reduced Cyclin T2 mRNA levels by ~ 60% relative to
cells transduced with control vector, while Cyclin T1
mRNA levels was not significantly affected (Figure 1B).
Two isoforms of Cyclin T2 are expressed in HeLa cells,
termed Cyclin T2a and Cyclin T2b that contain different
carboxyl termini due to differential splicing [29]. An
immunoblot analysis showed that the protein level of
Cyclin T2a was reduced when HeLa cells were trans-
duced with the CyclinT2 shRNA vector but not Cyclin
T1 shRNA vector (Figure 1C). Cyclin T2b protein is
expressed at a very low level in HeLa cells and it was
found to be reduced in cells transduced with Cyclin T2
shRNA vector but not Cyclin T1 shRNA vector (data
not shown). The shRNA vector against Cyclin T1 was
effective in depleting Cyclin T1 and had no effect on
Cyclin T2a as we have observed previously [10]. We
quantified the immunoblot relative to b-actin loading
control and specific protein expression in cells trans-
duced with MM control shRNA vector. We found
Cyclin T2a and Cyclin T1 protein levels were reduced
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Figure 1 shRNA against Cyclin T2 expressed from a lentiviral vector specifically and efficiently depletes CyclinT2 protein. (A) HeLa cells
infected at an m.o.i. of five with lentiviral vectors expressing a shRNA against Cyclin T2 (shRNA T2), Cyclin T1 (shRNA T1) or a control shRNA
against a mismatch sequence in Cyclin T1 (shRNA MM). Cultures were analyzed five days post infection by flow cytometry. HeLa cells not treated
with any shRNA were used as a control for flow cytometry analysis. The lentiviral vectors express a GFP marker protein. The unfilled region
represents GFP background level in non-treated HeLa cells. The percentages of GFP positive cells are indicated. (B) Total RNA was extracted from
HeLa cells transduced with shRNA T2 or shRNA MM after five days post infection and analyzed Cyclin T2, Cyclin T1 mRNA by quantitative real
time RT-PCR. The fold-change is indicative of the transcript levels in the shRNA T2 treated cells relative to the shRNA MM treated cells after
normalization to housekeeping gene, b-actin levels. (C) Immunoblot analysis of cell extracts prepared from HeLa cells transduced for five days
with shRNA T2, shRNA T1 or shRNA MM lentiviral vectors. Untransduced HeLa cells (Mock) were used as control. The immunoblots were
performed to analyze the levels of Cyclin T2, Cyclin T1, Cdk9, HEXIM1 and b-actin proteins. The band intensity was quantified using ImageJ and
presented below each panel.
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CyclinT2 or CyclinT1 shRNA vector, respectively. We
also observed that Cdk9 and HEXIM1 protein levels
were reduced ~10 and 27% and ~46 and 35%, respec-
tively, when either Cyclin T2 or Cyclin T1 was depleted.
Other studies have reported similar findings [14,17,27]
indicating that Cdk9 protein stability is linked to expres-
sion levels of its Cyclin partners. The reduction in levels
of HEXIM1 could be the result of the stoichiometry of
the 7SK RNP being disturbed when expression of Cyclin
T2 or T1 and consequently Cdk9 are reduced.
We examined the effect of Cyclin T2 and Cyclin T1
depletions on the growth rate of HeLa cells. Cultures
were transduced with Cyclin T2 or Cyclin T1 shRNA
vectors and five days later GFP positive cells in the cul-
tures were sorted by flow cytometry. GFP positive cells
were plated and MTT cell viability assays were carried
out on the sorted cells at days 0, 3, 7 and 9. Cells
expressing shRNA against Cyclin T2 or Cyclin T1 were
not significantly affected in their viability or growth rate
when compared with either mock or MM control trans-
duced cells (Figure 2). It is possible that Cyclin T2 and
Cyclin T1 may compensate each other in the activation
of many genes. To investigate this, we attempted to con-
currently deplete Cyclin T2 and Cyclin T1 but were not
successful (data not shown). We previously observed
that shRNA depletion of Cyclin T1 in monocytic MM6
cells had no observable effect on cellular viability or
growth [10] while depletion of the 55 kDa isoform of
Cdk9 in HeLa cells induced apoptosis [26]. We conclude
from these data that the depletion of Cyclin T1 or
Cyclin T2 under these conditions in HeLa cells does not
affect cellular growth.
Transcriptional profiling: validation and analysis of
microarray data
The data presented in Figures 1 and 2 demonstrate that
shRNA vectors against Cyclin T2 and Cyclin T1 are effi-
cient and specific, and depletion of either protein in HeLa
cells has no observable effect on cellular growth. This
observation raises the question about the redundancy of
these two Cyclin proteins for P-TEFb function. To address
this issue, we carried out transcriptional profiling with
DNA microarrays in cells depleted for Cyclin T2 or Cyclin
T1. HeLa cells were transduced with shRNA-Cyclin T1,
shRNA-Cyclin T2, or shRNA-MM Control lentiviral vec-
tor. At five days post transduction, cells were collected
and total RNA was isolated. Additionally, a portion of
cultures were monitored at this time for transduction effi-
ciencies by flow cytometry using the vector GFP marker
protein. Cultures were found to contain >97% GFP posi-
tive cells. Gene expression profiles were examined using
the Affymetrix GeneChip Human Genome U133 PLUS
2.0 array, which contains about 54,000 probe sets repre-
senting approximately 18,953 unique (non-redundant)
transcripts. Two independent biological replicate experi-
ments were carried out in this analysis.
To assess the reliability of the microarray data, several
mRNAs whose levels were differentially affected >1.2-
fold by Cyclin T2 or Cyclin T1 depletions were selected
for further analysis by quantitative real-time RT-PCR
assays. These mRNAs were: Cyclin T2 (reduced 3.2-fold
in DNA microarray data by Cyclin T2 depletion); Cyclin
T1 (reduced 2-fold in DNA microarray data by Cyclin
T1 depletion); HEXIM1 (reduced 2.5-fold in DNA
microarray data by Cyclin T2 depletion); CRM1
(reduced 1.7-fold in DNA microarray data by Cyclin T2
depletion); OAS1 (reduced 2.5- and 2.4-fold in DNA
microarray data by Cyclin T2 and Cyclin T1 depletions,
respectively); MFAP5 (reduced 6.5- and 3.9-fold in DNA
microarray data by Cyclin T2 and Cyclin T1 depletions,
respectively); CDKN1C (reduced 2.2 and 2.6-fold in
DNA microarray data by Cyclin T2 and Cyclin T1
depletions, respectively). RNA levels in real-time RT-
PCR assays were normalized to GAPDH as the mRNA
for this house-keeping gene was unaffected by Cyclin T2
or Cyclin T1 depletions. The transcript levels of the
selected genes were analyzed from four independent
biological replicate experiments. As shown in Figure 3,
the changes in mRNA abundance in shRNA-Cyclin T2
and shRNA-Cyclin T1 treated cells relative to shRNA-
MM control (set arbitrarily at 1.0) are in accordance
with the trend seen in the microarray data. It should be
noted that microarray data tend to be more compressed
than that of quantitative real-time RT-PCR assays
Figure 2 Cyclin T2 depletion does not affect HeLa cell growth.
HeLa cells transduced with lentiviral shRNA vectors (shRNA T2,
shRNA T1, shRNA MM) for 5 days were sorted by flow cytometry for
GFP expression. The sorted (105 cells) cells were plated and MTT cell
growth and viability assay was performed on days 0, 3, 7 and 9.
Results are expressed as the percentage of viable cells compared
with MM control shRNA transduced cells.
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[30,31]. These data indicate that the microarray data are
likely in general to be reliable.
Cellular genes are differentially affected when either
Cyclin T2 or Cyclin T1 are depleted in HeLa cells
We used the transcriptional profiling data from two inde-
pendent biological experiments to identify the mRNAs
that were either down-regulated or up-regulated > 1.2-
fold (p-value < 0.05) by either Cyclin T2 or Cyclin T1
depletions relative to their expression in cells transduced
with the MM control shRNA vector. The 1.2-fold cut-off
has been used in other transcriptome analysis studies
[32,33]. When a fold cut-off of 1.5 was examined, 96 total
genes were down-regulated in Cyclin T2 depletions and
242 total genes were down-regulated in Cyclin T1 deple-
tions. There were 75 and 147 genes up-regulated >1.5-
fold when either Cyclin T2 or CyclinT1 was depleted,
respectively. The intersection of Cyclin T2 and Cyclin T1
down-regulated genes >1.5-fold contained 35 total com-
mon genes, while the intersection of up-regulated genes
contained 20 common genes (data not shown). When a
fold cut-off of 2.0 was examined, 17 total genes were
down-regulated in Cyclin T2 depletions and 71 total
genes were down-regulated in Cyclin T1 depletions.
There were 16 and 28 genes up-regulated >2.0-fold when
either Cyclin T2 or CyclinT1 was depleted, respectively.
The intersection of Cyclin T2 and Cyclin T1 down-regu-
lated genes >2.0-fold contained just 5 total common
genes, while the intersection of up-regulated genes
contained 9 common genes (data not shown). It is likely
that analyzing a high fold cut-off (>1.5- and >2.0-fold)
will result in a gene list containing a number of false-
negatives; conversely, analyzing a small fold cut-off (1.2-
fold) will likely result in a gene list containing a number
of false-positives. However, our analysis of the microarray
data involved identification of differentially expressed
genes using a student t-test and the Benjamini-Hochberg
method was applied to correct for false discovery rate.
The 1.2-fold cut-off was therefore chosen to include a
wide representative of genes whose expression was chan-
ged by the shRNA treatment. Thus our gene lists are
likely to contain relatively few false-negatives at the
expense of containing some false-positives.
As seen in the heat map in Figure 4, there are sets of
genes that are either down-regulated or up-regulated in
Cyclin T2 depletions, and different sets of genes that are
down-regulated or up-regulated in Cyclin T1 depletions.
The genes are arranged such that the up-regulated
genes are at the top and the down-regulated genes at
the bottom of the heat map. In addition, there are other
sets of genes that are down-regulated or up-regulated in
both Cyclin T2 and Cyclin T1 depletions.
As shown in the Venn diagram in Figure 5, 292 total
genes were down-regulated >1.2-fold when Cyclin T2 was
depleted and 631 total genes were down-regulated >1.2-
fold when Cyclin T1 was depleted. A total of 111 genes
were up-regulated >1.2-fold in Cyclin T2 depletions and a
total of 287 genes were up-regulated >1.2-fold in Cyclin
T1 depletions (Figure 5B). The intersection of Cyclin T2
and Cyclin T1 down-regulated genes contains 100 total
common genes, while the intersection of up-regulated
genes contains 45 common genes.
Redundant and non-redundant regulation of genes by
Cyclin T2 or Cyclin T1 in HeLa cells
As expected, we identified genes that were up- or
down-regulated by depletion of Cyclin T2 and Cyclin
T1 (Figures 4, 5, 6). However, we were interested in
characterizing the genes whose expression was down-
regulated by the depletions, as these are more likely to
be directly regulated by Cyclin T2 or Cyclin T1. The 10
genes showing the most down-regulation upon Cyclin
T2 or Cyclin T1 depletion are shown in Table 1. Genes
that were down-regulated only in Cyclin T2 depletions
included Heat shock protein 3, HEXIM1 and Ankyrin
repeat domain 12, while genes that were down-regu-
lated only in Cyclin T1 depletions included Ankyrin
repeat domain 29 and serine threonine kinase 38
(Table 1). Genes that were down-regulated in both
Cyclin T2 and Cyclin T1 depletions include Forkhead
box Q1 and Dual specificity phosphatase 16 (Table 2)
indicating that genes important in immune response are








Figure 3 Validation of microarray data. Total RNA was extracted
from four independent HeLa cell infections with indicated shRNA
vectors for five days including aliquots of RNA for microarray
analysis. Quantitative real-time RT-PCR was carried out to measure
the expression level of indicated mRNA. The fold-change was
calculated and represents the change in transcript levels in shRNA
T2 or T1 infected cells relative to shRNA MM treated cells after
normalization to housekeeping gene, GAPDH. Average fold-change
from the four independent infections is presented. * p < 0.05,
** p < 0.005, *** p < 0.0005 in a paired t-test.
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Gene Ontology and KEGG pathway analyses were car-
ried out on the gene lists based on z-scores. The z-score is
based on hypergeometric distribution and is calculated
from the total number of genes in the array, the number
of genes on the specific pathway, the number of genes on
the gene list. Thus, a z-score of 0 indicates no enrichment,
i.e., the expected number of hits is observed. A positive z-
score indicates enrichment and a negative z score indicates
under-representation.
Gene Ontology grouping showed that genes down-
regulated by Cyclin T2 depletion included genes
involved in response to stimulus and stress, negative
regulation of metabolism and transcription, signal trans-
duction and muscle development (Table 3). Genes
down-regulated by Cyclin T1 depletion included genes
involved in metabolism, intracellular signalling cascade,
regulation of apoptosis, cell growth, transport, regula-
tion of DNA repair, and antigen processing and presen-
tation (Table 3). Genes commonly down-regulated by
either Cyclin T2 or T1 depletion included genes
involved in cellular processes, apoptosis, cell death,
myeloid cell differentiation and lymphoid organ devel-
opment (Table 3).
The gene list was also analyzed and grouped based on
KEGG pathways (Figure 6). Genes affected by Cyclin T2
depletion were over-represented in signalling pathways
(specifically MAPK, GnRH, and insulin signalling) and
vesicular transport, while genes affected by Cyclin T1
depletion included genes involved in metabolism (lipid
and inositol phosphate) and biosynthesis (diterpenoid and
streptomycin). Interestingly, genes involved in MAPK and
GnRH signalling pathways were over-represented in both
Cyclin T2 and T1 depletions. While the over-represented
pathways are similar, the identity of the genes are different
suggesting that there is a limited degree of redundancy in
the genes regulated by Cyclin T2 and Cyclin T1 even
though there is a set of genes under specific control of
either Cyclin T.
Figure 4 Differential expression of genes following Cyclin T2 or Cyclin T1 knockdown. Heat map of genes differentially expressed in HeLa
cells infected with lentiviral shRNA vectors against Cyclin T2 or Cyclin T1 compared to control MM. Up regulated genes are in red and down
regulated genes are in green. The insets represent an enlargement of a portion of the heat map.
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Dysregulation of specific genes could be a predisposition
for development of a diseased state and because P-TEFb is
responsible for transcriptional elongation of most protein
coding genes [34], we next looked at the potential link
between our gene list and diseases using the disease-gene
link in DAVID http://david.abcc.ncifcrf.gov. As expected,
the Cyclin T1 specific gene-list was over-represented for
genes involved in HIV-1 infection. The other diseases
implicated include dementia, cancers (colorectal and blad-
der), age related macular degeneration, cholesterol/LDL
related and gallstones (Table 4). Cyclin T2 specific genes
were over represented only in the aging process while
metabolic and cardiovascular diseases were linked to
genes that were commonly down-regulated upon Cyclin
T2 or Cyclin T1 depletion (Table 4).
Discussion
In this study, we employed shRNA lentiviral vectors and
cDNA microarrays to profile changes in mRNA expression
levels in HeLa cells in response to long term depletion of
the P-TEFb regulatory subunits Cyclin T2 and Cyclin T1.
Using a 1.2-fold cut-off, we found that 292 and 631 genes
were down-regulated upon depletion of Cyclin T2 and
Cyclin T1, respectively. On the other hand, 111 and 287
genes were up-regulated upon depletion of Cyclin T2 or
Cyclin T1, respectively. Interestingly, expression of 100
and 45 genes were commonly down-regulated or up-regu-
lated, respectively, when either Cyclin was depleted. These
data indicate that there is limited redundancy in the genes
regulated in HeLa cells by either of the Cyclin partners of
Cdk9 in P-TEFb complexes.
P-TEFb is required for the transcriptional elongation
of most protein coding genes in mammals [34]. The
P-TEFb complex containing Cyclin T1 has been exam-
ined in detail because it is an essential host factor in
HIV-1 gene expression. However, Cyclin T2 has been
reported to play a role in myocyte differentiation
[35,36]. In this study, we found that depletion of either
Cyclin T2 or Cyclin T1 under our conditions did not
significantly affect cell growth or viability in HeLa cells.
Thus, it is likely that a certain degree of redundancy is
built into the genes regulated in transformed cells by
either Cyclin T1and Cyclin T2. A recent report found
that a Cyclin T2 knock-out resulted in embryonic lethal-
ity in mice [27]. In the same study, it was also reported
that Cyclin T2 and T1 serve mostly redundant but also
some non-redundant functions in murine ES cells [27].
In C.elegans, ablation of either Cyclin T2 or Cyclin T1
had no deleterious effect, indicating a high degree of
redundancy in the functions of the Cyclins, although
depletion of both Cyclins resulted in embryonic lethality
[37]. Thus, there appears to be a degree of redundancy
in the role of Cyclin T2 and T1 across species.
The expression of Cyclin T2 and T1 varies in primary
hematopoietic cells. While Cyclin T2 is constitutively
expressed in resting CD4+ T-cells and monocytes, Cyclin
T1 expression is very low in these cells [8,12]. Activation
of CD4+ T-cells and differentiation of monocytes into
macrophages up-regulates Cyclin T1 levels by post-tran-
scriptional mechanisms while Cyclin T2 level remains
relatively constant [8,10,12,38,39]. We speculate that the
expression pattern of both Cyclins reflect the nature of
the genes that they regulate in these cells. We found that
genes involved in metabolism (inositol phosphate and
glycosphinglipid), biosysnthesis (Diterpenoid), and degra-
dation (phenolics) were down-regulated upon Cyclin T1
and not Cyclin T2 depletion, whereas Kohoutek et al.
[27] report that genes involved in cell cycle and commu-
nication were down-regulated. When Cyclin T2 was
depleted, genes of signaling pathways (MAPK, GnRH and
Insulin) and vesicular transport were down-regulated,
while the Kohoutek study [27] found that the mRNAs of
Notch, Wnt and TGFb signaling and autophagy-related
genes were affected. These differences in the signaling
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Figure 5 Summary of pairwise comparisons for genes affected
in shRNA T2 and shRNA T1 infected HeLa cells. The Venn
diagram represents the following individual pairwise comparisons:
down regulated genes- shRNA T2 (blue circle) vs. shRNA T1 (orange
circle), up regulated genes- shRNA T2 (purple circle) vs. shRNA T1
(green circle) each compared to shRNA MM. Number in parentheses
represents the total number of genes whose expression was
changed for that comparison. The numbers within each circle
represents the genes unique to that comparison. The number in the
intersection of the gene sets representing the shared genes whose
expression was changed is indicated.
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pathways whose expression specifically changes upon
Cyclin T2 depletion is likely due to the different experi-
mental system used– the Kohoutek study used siRNA
depletions in mouse ES cells, while we used shRNA
depletions in HeLa cells [27]. We found that genes
involved in signaling, cell junction, long term potentia-
tion of nerve synapse and Huntington’s disease were
commonly down-regulated when either Cyclin was
depleted. This suggests that Cyclin partners (both T2 and
T1) of Cdk9 play a role in the nervous system and under-
scores the importance of P-TEFb in key cellular
processes.
In most cell types examined so far, it appears that Cyclin
T1 is the major regulatory subunit in P-TEFb complexes,
while Cyclin T2a and T2b are minor regulatory subunits.
This suggests that more genes are regulated by Cyclin T1
than T2. In agreement with this notion, we found that in
HeLa cells there were 631 genes repressed by Cyclin T1
depletion, while 292 genes were repressed by Cyclin T2
depletion. In contrast, Kohoutek et al. found that in
mouse ES cells, 59 and 76 genes were affected when either
Cyclin T1 or Cyclin T2 were depleted, respectively [27].
We had reported earlier that Cyclin T1 depletion
repressed 644 genes in PMA+ionomycin activated Jurkat
cells, 965 genes in PMA-treated MM6 monocytic cells,
and 778 genes repressed in LPS- treated MM6 cells [14].
It therefore appears that more genes are under the control
of Cyclin T1 than Cyclin T2, with the exception of mouse
ES cells and perhaps other select primary cell types. While
P-TEFb is involved in expression of most protein coding
genes, the number of genes affected by the depletion of
Cyclin T2 or Cyclin T1 in our and the Kohoutek et al.
study [27] is not very high. We speculate that there could
be a subset of genes having a low threshold requirement
for functional P-TEFb which are not affected by the reduc-
tion in Cyclin T2 or Cyclin T1 expression following
shRNA depletions. These genes may be affected if Cyclin
T2 or Cyclin T1 is genetically ablated. It is also possible
Genes commonly downregulated 
Cyclin T2 specific genes 
Cyclin T1 specific genes 
Figure 6 KEGG pathway analysis of genes regulated by Cyclin T2 and Cyclin T1. KEGG pathway grouping was done based on z-score
following Gene Ontologic analysis of the unique and shared gene sets down regulated following HeLa cell infection with shRNA T2 or shRNA
T1 lentiviral vectors compared to cells infected with control shRNA MM vector. The pie charts show over represented pathways for indicated
conditions. The z-scores are also presented.
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Table 1 List of genes down regulated upon Cyclin T2 and Cyclin T1 depletion
Gene name Gene ID Gene
identifier




Top 10 genes down-regulated by Cyclin T2 depletion
Heat shock 27 kDa protein 3 HSPB3 NM_006308 206375_s_at 5 -3.12 0.0368
G protein-coupled receptor 137B GPR137B NM_003272 204137_at 1 -2.3 0.0251
ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 NM_005502 203504_s_at 9 -2.1 0.0336
Ankyrin repeat domain 12 ANKRD12 X80821 216563_at 18 -2.06 0.0166
Ataxin 1 ATXN1 AW235612 203231_s_at 6 -2.04 0.0111
Coronin 6 CORO6 NM_032854 1552301_a_at 17 -2.04 0.0330
Growth arrest-specific 1 GAS1 NM_002048 204457_s_at 9 -2.02 0.0303
ATG16 autophagy related 16-like 1(S. cerevisiae) ATG16L1 NM_017974 220521_s_at 2 -1.95 0.0375
Hexamethylene bis-acetamide inducible 1 HEXIM1 NM_006460 202815_s_at 17 -1.94 0.0482
Calcium channel, voltage-dependent, beta 2 subunit CACNB2 NM_000724 207776_s_at 10 -1.85 0.0178
Top 10 genes down-regulated by Cyclin T1 depletion
Chemokine (C-X-C motif) ligand 14 CXCL14 NM_004887 218002_s_at 5 -3.55 0.0403
Transmembrane protease, serine 3 TMPRSS3 AB038160 223949_at 21 -2.59 0.0361
Ankyrin repeat domain 29 ANKRD29 AI307802 238332_at 18 -2.36 0.0433
FK506 binding protein 1B, 12.6kDa FKBP1B NM_004116 206857_s_at 2 -2.16 0.0108
Syndecan binding protein (syntenin) SDCBP NM_005625 203231_s_at 8 -2.09 0.0366
DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 DDX18 NM_006773 205763_s_at 2 -1.9 0.0217
Eukaryotic translation initiation factor 4E binding protein
2
EIF4EBP2 U88989 224653_at 10 -1.89 0.0168
Serine/threonine kinase 38 STK38 NM_007271 1553117_a_at 6 -1.68 0.0196
Cyclin G2 CCNG2 AW134535 202769_at 4 -1.65 0.0129
S100 calcium binding protein A4 S100A4 NM_002961 203186_s_at 1 -1.62 0.0117
Genes with greatest down regulation specific to Cyclin T2 or Cyclin T1 depletion. The 10 genes with greatest decrease in expression following Cyclin T2 or Cyclin
T1 depletion are listed (p 0.05). All fold-changes are relative to MM control. Minimum expression level of genes in MM control was arbitrarily chosen as 3.0.










Aldo-keto reductase family 1, member C2 AKR1C2 U05598 209699_x_at 10 -2.84 -2.23 0.0153
Bone morphogenetic protein 2 BMP2 AA583044 205289_at 20 -2.46 -2.18 0.0239
Forkhead box Q1 FOXQ1 AI676059 227475_at 6 -1.98 -2.18 0.0415
Caspase 1, apoptosis-related cysteine peptidase
(interleukin 1, beta, convertase)
CASP1 U13699 211367_s_at 11 -1.95 -1.85 0.048914
Dual specificity phosphatase 16 DUSP16 AB051487 224832_at 12 -1.94 -1.32 0.0407
Pre-B-cell leukemia transcription factor
interacting protein 1
PBXIP1 AI935162 214177_s_at 1 -1.90 -2.08 0.0185
Bromodomain containing 9 BRD9 NM_024786 1552283_s_at 5 -1.82 -1.7 0.007266
Transcription factor 7-like 1 (T-cell specific, HMG-
box)
TCF7L1 NM_031283 221016_s_at 2 -1.81 -1.8 0.010119
Peroxidasin homolog (Drosophila) PXDN D86983 212013_at 2 -1.76 -1.83 0.0127
1-acylglycerol-3-phosphate O-acyltransferase 3 AGPAT3 BC004219 223184_s_at 21 -1.61 -1.79 0.01225
Genes commonly down regulated when either Cyclin T2 or Cyclin T1 is depleted. The 10 genes with greatest decrease in expression following Cyclin T2 or Cyclin
T1 depletion are listed (p ≤ 0.05). All fold-changes are relative to MM control. Minimum expression level of genes in MM control was arbitrarily chosen as 3.0.
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Table 3 Gene Ontology (GO) analysis of the gene list based on z-score
Ontology List Array z-score
Gene Ontologic analysis of genes down-regulated by Cyclin T2 depletion
Biological process unknown 14 566 3.38
Response to chemical stimulus 8 331 2.45
Negative regulation of metabolism 7 241 2.83
Negative regulation of cellular metabolism 6 204 2.65
Negative regulation of transcription 6 167 3.22
Negative regulation of transcription, DNA-dependent 6 109 4.56
Enzyme linked receptor protein signaling pathway 5 176 2.33
Chromatin modification 4 140 2.09
Negative regulation of transcription from RNA polymerase II promoter 4 66 3.98
Regulation of kinase activity 4 126 2.33
Regulation of transferase activity 4 128 2.3
Regulation of Rho protein signal transduction 3 69 2.68
Regulation of small GTPase mediated signal transduction 3 93 2.05
Calcium mediated signaling 2 22 3.69
chloride transport 2 43 2.31
Energy reserve metabolism 2 34 2.75
Frizzled signaling pathway 2 17 4.32
Neurotransmitter transport 2 40 2.44
Oligosaccharide metabolism 2 13 5.05
Protein amino acid ADP-ribosylation 2 24 3.49
Protein processing 2 46 2.18
Ras protein signal transduction 2 30 3.01
Regulation of cyclin dependent protein kinase activity 2 37 2.59
Response to oxidative stress 2 46 2.18
Response to protein stimulus 2 44 2.26
Response to unfolded protein 2 44 2.26
Striated muscle development 2 39 2.49
Transmembrane receptor ptotein tyrosine phosphatase signaling pathway 2 7 7.12
Gene Ontologic analysis of genes down-regulated by Cyclin T1 depletion
Metabolism 178 6465 -2.45
Cellular metabolism 158 6076 -3.31
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 64 2908 -3.24
intracellular signaling cascade 43 1038 2.05
death 28 555 2.72
cell death 27 551 2.51
apoptosis 26 524 2.53
programmed cell death 26 525 2.52
regulation of apoptosis 17 342 2.04
Regulation of programmed cell death 17 343 2.02
small GTPase mediated signal transduction 15 291 2.06
Cellular morphogenesis 14 247 2.36
Regulation of enzyme activity 13 235 2.18
Protein folding 11 197 2.04
Anion transport 10 160 2.32
Growth 10 174 2.04
Cell growth 9 139 2.32
Ramakrishnan et al. BMC Research Notes 2011, 4:260
http://www.biomedcentral.com/1756-0500/4/260
Page 10 of 16
that a certain degree of redundancy exists for genes regu-
lated by Cyclin T2 and Cyclin T1 as was seen here and by
Kohoutek et al.[27]. In addition to Cyclin T2 and Cyclin
T1, Cdk9 has been reported to associate with Cyclin K
[40,41]. While we have not examined the role of Cyclin K
in this study, it is possible that when Cyclin T2 or Cyclin
T1 is depleted, the Cdk9-CyclinK complex might provide
an additional level of redundancy to the regulation of
genes by P-TEFb.
In our study, genes involved in negative regulation of
transcription and metabolism were down-regulated upon
Cyclin T2 depletion, while genes involved in cell growth,
metabolism, apoptosis, cellular morphogenesis and sig-
naling were down-regulated upon Cyclin T1 depletion.
Genes that were commonly down-regulated when either
Cyclin T2 or T1 was depleted included the Gene Ontolo-
gic class of positive and negative regulation of cellular
processes, apoptosis, negative regulation of cell prolifera-
tion and innate immune response. It is possible that the
classes of genes affected by inhibition of Cdk9 [42] and
those found in our study are involved in a cross-talk
depending on the cell type and the transcriptional
requirement in response to environmental signals,
although more work is required to establish this link.
As discussed above, expression of Cyclin T2 is consti-
tutive while Cyclin T1 protein expression is inducible
depending on the activation or differentiation status of
primary T-cells and macrophages, respectively [8,12]. In
the present study, the number of genes down-regulated
when Cyclin T1 is depleted is much more (631) than
those down-regulated when Cyclin T2 is depleted (292).
This could be representative of the transcriptional
requirements of the cell. When the cells are in resting or
undifferentiated stage, the transcriptional program and
Table 3 Gene Ontology (GO) analysis of the gene list based on z-score (Continued)
Endocytosis 9 130 2.54
Regulation of Cyclin dependent protein kinase activity 4 37 2.72
Antigen processing 3 31 2.12
RNA metabolism 3 464 -3.11
RNA processing 3 383 -2.66
post-Golgi vesicle mediated transport 2 17 2.07
Protein export from nucleus 2 8 3.58
Regulation of DNA repair 2 7 3.89
Antigen presentation, endogenous antigen 2 16 2.17
Antigen processing, endogenous antigen via MHC class I 2 17 2.07
Gene Ontologic analysis of genes down-regulated by Cyclin T2 or Cyclin T1 depletion
Regulation of cellular process 25 3058 2.04
Regulation of cellular physiological process 24 2840 2.17
Negative regulation of biological process 11 748 3.33
Negative regulation of cellular process 10 696 3.08
Negative regulation of cellular physiological process 9 631 2.89
Negative regulation of physiological process 9 655 2.77
Positive regulation of biological process 9 627 2.91
Positive regulation of cellular process 9 540 3.42
Apoptosis 8 524 2.93
Cell death 8 551 2.77
Cell proliferation 8 499 3.09
Negative regulation of cell proliferation 6 147 5.63
Regulation of apoptosis 6 342 2.91
Innate immune response 2 63 2.72
Positive regulation of I-B/NF-B cascade 2 76 2.37
Myeloid cell differentiation 2 37 3.88
Hemopoietic or lymphoid organ development 2 93 2.01
A GO analysis of the gene sets unique (192 and 531) and shared (100) to Cyclin T2 and Cyclin T1 depletion, respectively, was carried out and grouped based on
z-score. Only GO categories that were over represented with at least 2 genes were considered. The “List” value is the number of affected genes from the gene
list in the group. The “Array” value shows the total number of genes on the microarray that are in this gene ontology. The “z-score” is the expected number of
genes in a GO term, subtracted from the observed number of genes. This value is divided by the standard deviation of the observed number of genes.
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Table 4 Functional annotation of genes associated with disease
Condition Disease/Processes Genes
Specific to Cyclin T2 depletion Aging Fas (TNF receptor superfamily, member 6)
N-acteyltransferase 1 (Arylamine N-acteyltransferase)
ATP-binding cassette, sub-family A (ABC1), member 1
Superoxide dismutase 2, mitochondrial
Hemochromatosis
Specific to Cyclin T1 depletion HIV-1 biology Cyclin dependent kinase 9 (Cdk9)
Cyclin T1
Granulin
Major histocompatibility complex, Class II, DM alpha
Tubulin, beta 6
Dementia Amyloid beta (A4) precursor protein (peptidase Nexin-II, Alzheimer disease)
Very low density lipoprotein receptor
Estrogen receptor 1
Microtubule-associated protein (Tau)
Serpin peptidase inhibitor, clade 1 (Neuroserpin), member 1
Synuclein, alpha (non A4 component of amyloid precursor)
Cholesterol, LDL Proprotein convertase Subtilisin/Kexin type 9
Low density lipoprotein receptor (familial hypercholesterolemia)
Apolipoprotein C-1
Low density lipoprotein receptor adaptor protein 1
Gallstones Low density lipoprotein receptor-related protein associated Protein 1




very low density lipoprotein receptor
Microsomal Glutathione S-transferase 1
Pleckstrin homology domain containing, family A (phosphoinositide binding
specific) member 1
Colorectal cancer Platelet-derived growth factor receptor-like
V-HA-Ras Harvey rat sarcoma viral oncogene homolog
Mutated in colorectal cancers
Bladder cancer V-HA-Ras Harvey rat sarcoma viral oncogene homolog
Fibroblast growth factor receptor 3 ( Achondroplasia, Thanatophoric
dwarfism)
Common to Cyclin T2 and Cyclin T1
depletion
Metabolic Fatty acid binding protein 3, muscle and heart (mammary-derived growth
inhibitor)
ATPase, class 1, Type 8B, member 1
Heme oxygenase (decycling) 1
Syndecan 2 (heparin sulfate proteoglycan 1, cell surface-associated,
fibroglycan)
Bone morphogenetic protein 2
Calmodulin 1 (Phosphorylase kinase, delta)
Hydatidiform mole associated and imprinted
Scavenger receptor class B, member 1
Smad, mothers against DPP homolog 4 (Drosophila)
Metabolic TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
psudoinflammatory)
Fibrillin 1 (Marfan syndrome
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metabolism needs to be regulated to maintain homeosta-
sis and this may be reflected in the nature of the genes
down-regulated upon Cyclin T2 depletion which include
negative regulation of metabolism and transcription. The
relevance of constitutive expression of Cyclin T2 is also
underscored in the regulation of kinase activity, signal
transduction, energy reserve metabolism. Once the cells
are activated or undergo a program of differentiation, the
regulation of genes probably shifts to those under control
of Cyclin T1. As the transcriptional and metabolic needs
of the cells increase in response to activation or differen-
tiation signals, the nature of the genes controlled by
Cyclins change to active cellular metabolism, nucleic acid
metabolism, apoptosis and cell growth. In this context,
our results are in agreement with those of Kohoutek
et al. [27] as they found that depletion of Cyclin T2 and
not Cyclin T1 affected genes important for early embryo-
genesis while genes involved in cell communication was
repressed when Cyclin T1 and not Cyclin T2 was
depleted. We found that the number of genes affected by
depletion of Cyclin T2 is lower than those affected by
Cyclin T1 depletion. It is likely that the importance of
multiple P-TEFb complexes in a cell lies probably not
just in the number but the identity and function of the
regulated genes. For instance, we found that Ankyrin
repeat domain 12 was down-regulated when Cyclin T2
and not Cyclin T1 was depleted, while Ankyrin repeat
domain 29 was repressed when Cyclin T1 and not Cyclin
T2 was depleted. Ankyrin repeat domains mediate pro-
tein-protein interactions and are observed in bacterial
and eukaryotic proteins [33,34]. In particular Ankyrin
repeat domains have been reported to be present in IB
proteins and mediate interaction with NF-B [35]. These
domains are involved in important biological functions
like transcriptional regulation, cell cycle and differentia-
tion [36]. As discussed above, we note that there are both
similarities and differences between the Kohoutek et al.
[27] study in ES cells and our study in HeLa cells with
respect to genes regulated by Cyclin T2 and Cyclin T1. It
is likely that the differences arise because of experimental
approaches. Despite these differences, the data presented
in our study and by Kohoutek and colleagues should
prove useful for researchers to mine for studies of speci-
fic genes or pathways of interest.
In summary, we have carried out transcriptional pro-
filing to gain an insight into the genes regulated by the
two distinct regulatory subunits of P-TEFb, Cyclin T2
and Cyclin T1. We found that there is limited redun-
dancy in the genes under control of either Cyclins. The
identity of the genes regulated by Cyclin T2 and T1 and
the expression patterns of the Cyclin proteins are con-
sistent with the notion that Cyclin T2 plays an impor-
tant role in regulating genes involved in quiescent cells,
while Cyclin T1 plays an important role in regulating
genes in metabolically active cells.
Methods
Cell culture, Cell extracts and immunoblots
HeLa cells were purchased from American Type Culture
Collection (ATCC) and were maintained in DMEM (Invi-
trogen) with 10% FBS, 100 units of penicillin, and 100 μg/
ml streptomycin. Cell extracts were prepared by incubat-
ing cells in lysis buffer (50 mM Tris, 120 mM NaCl, 0.5%
NP-40) containing protease inhibitors (2 μg/ml aprotinin,
1 μg/ml leupeptin, 2.5 mM phenylmethylsulfonyl fluoride)
as described previously [11]. Protein concentrations were
determined by a Bio-Rad protein assay, and 20 μg of total
protein was loaded onto 10% SDS-PAGE gels. The proce-
dure for immunoblots using enhanced chemiluminescence
for detection has been previously described [43]. Antibody
to b- actin was purchased from Sigma, and other antibo-
dies were purchased from Santa Cruz Biotechnology.
ShRNA design, Lentiviral production and Flow Cytometry
The target short hairpin RNA (shRNA) sequences used
in this study were: shRNA CycT1: GCAGCGTCT-
TAACGTCTCA; shRNA -Cyc T2, GCCAGTACCTC-
TAA; shRNA -Control (MM), GCTATAGCTGTTC
Table 4 Functional annotation of genes associated with disease (Continued)
Cardiovascular Neural precursor cell expressed, developmentally downregulated 4-like
Cyclin dependent kinase inhibitor 1C (p57, Kip2)
Caspase 1, Apoptosis-related Cysteine peptidase (Interleukin 1, beta,
convertase)
Heme oxygenase (decycling) 1
Calmodulin 1 (Phosphorylase kinase, delta)
Poliovirus receptor-related 2 (Herpesvirus entry mediator B)
Scavenger receptor class B, member 1
TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
psudoinflammatory)
The gene sets were investigated for potential link to diseases in a functional annotation analysis using DAVID. The disease states and the identity of genes
potentially associated with it in the gene sets are presented.
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TAGTTC. The subcloning protocol into the FG12
self-inactivated lentiviral vector that carries an eGFP
expression cassette has been described before [10]. The
FG12 vector does not encode any viral gene products [44].
Briefly, oligonucleotides containing the target sequences
with restriction enzyme site compatible overhangs were
annealed and inserted into a hU6-1 plasmid vector imme-
diately after the human U6 promoter. The shRNA expres-
sing cassette was then subcloned into the FG12 vector.
Stocks of the FG12 lentiviral vectors pseudotyped with
vesicular stomatitis virus (VSV)-G were produced by
either calcium phosphate mediated or Lipofectamine 2000
(Invitrogen) transient transfection of HEK-293T cells.
Briefly, HEK-293T cells were cultured in 100-mm dishes
in DMEM (Invitrogen) containing 10% FBS (Invitrogen),
100 units of penicillin, and 100 μg/ml streptomycin. The
cells were cotransfected with 5 μg of each plasmid: vector
plasmid, the VSV-G expression plasmid pHCMV-G, and
the HIV-1 lentiviral packaging plasmids pRSV/REV and
pMDLg/pRRE. Media was changed the following day and
supernatants were passed through a 0.45-μm pore size
sterile filter 48 hours post-transfection. Viral supernatants
not used immediately were stored in aliquots at -80°C.
HeLa cells were transduced at a multiplicity of infection
(m.o.i.) of five in the presence of 5 ng/ml polybrene
(Sigma). Transduction efficiencies were determined five
days after lentiviral infection by suspending cells at 1 ×
106 cells/ml in phosphate-buffered saline (PBS) with 2%
FBS and the percentage of GFP positive cells were deter-
mined by flow cytometry using a Beckman-Coulter
XL-MCL cytometer.
MTT cell viability assay
HeLa cells transduced with lentiviral shRNA vectors
against Cyclin T1, Cyclin T2 and Control (MM) were
sorted for GFP expression using a flow cytometer. One
hundred thousand sorted cells were plated and at differ-
ent time points MTT was added at 5 mg/mL. After an
incubation of 4 h, the formazon product was dissolved
in acidified isopropanol and color estimated at 560 nm.
Microarray analysis
HeLa cells were transduced with shRNA lentiviral vectors
against Cyclin T2, Cyclin T1 or MM control as described
above. Two independent biological replicate experiments
were carried out. The cells were harvested five days post-
transduction and total RNA for microarray analysis was
extracted using Qiagen RNeasy Kit according to manu-
facturer’s protocol and RNA quality was determined
using an Aligent 2100 Bioanalyzer and the Nano-Drop
ND-1000 Spectorphotometer. The RNA was reverse
transcribed and the resultant cDNA transcribed using T7
RNA polymerase and biotinylated ribonucleotides to gen-
erate labeled cRNA. Fragmented cRNA was hybridized to
U133 plus 2.0 human gene chips (Affymetrix) containing
nearly 55,000 probe sets representing over 18,953 tran-
scripts. Following washing and staining, the arrays were
scanned using an Affymterix Gene Chip Scanner 3000,
normalized to the medium intensity and analyzed. The
primary microarray data have been deposited in the
NCBI GEO database and are accessible through GEO
Series accession number, GSE28339http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE28339. The microar-
ray data was analyzed using the GeneSifter microarray
data analysis system (VizX Labs LLC, Seattle, WA; http://
www.genesifter.net). The program identifies differentially
expressed genes and establishes the biological signifi-
cance based on Gene Ontology (GO) http://www.geneon-
tology.org and KEGG pathways http://www.genome.jp/
kegg/pathway.html. The CEL files for each array were
uploaded into GeneSifter and the data was normalized
and log transformed using the GC-RMA algorithm. GC-
RMA is the modified version of RMA (robust multi-array
average) that uses probe sequence information for the
background correction [45]. Differentially expressed
genes were identified using Student t-test and a threshold
of 1.2 was used to limit the data set to genes. Correction
for multiple testing was performed using the Benjamini-
Hochberg method to correct for false discovery rate.
The biological process ontologies and KEGG pathway
terms associated with the differentially expressed genes
were examined using a z-score report. The z-score report
identifies ontologies or pathway terms that are significantly
over-represented in a gene list [46]. Thus, a positive
z-score indicates that more genes than expected beyond
random chance fulfil the criteria (fold change and statisti-
cal criteria) in a certain group or pathway suggesting
changes in that group or pathway. A negative z-score indi-
cates that there were fewer genes than expected beyond
random chance that met the fold change and statistic cri-
teria. A functional annotation analysis was performed
using DAVID http://david.abcc.ncifcrf.gov[47,48] to iden-
tify the link between diseases and the gen lists.
Real-time PCR analysis
Microarray data were validated by quantitative real-time
RT-PCR using the Bio-Rad MyIQ single color detection
system as previously described [14]. Briefly, 1 μg of cellular
RNA was reverse transcribed using the iScript cDNA
synthesis kit (Bio-Rad). Quantitative real-time PCR was
performed using the iQ SYBR Green Supermix (Bio-Rad)
in the Bio-Rad iCycler. Primers for quantitative PCR were
designed Beacon Designer 2.0 (Premier Biosoft). Primers
used were: Cyclin T2 (forward) GGCGGAGGAG-
GAAGTGTCATG, Cyclin T2 (reverse) GCGGCTCGG
CGTGTTCTC; Cyclin T1 (forward) AACCTTCGCCG
CTGCCTTC, Cyclin T1 (reverse) ACCGTTTGTTGT
TGTTCTTCCTCTC, HEXIM1 (forward) GCAGTT
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GGAAGTTGGCAGGTG, HEXIM1 (reverse) TCAGT
TCTCCTCCGCCTCCTC; OAS1 (forward) GAGCCT-
CATCCGCCTAGTCAAG, OAS1 (reverse) CCCAAGCA-
TAGACCGTCAGGAG; MFAP5 (forward) CCTGGCTT
TCTTGCTCTCCCTC, MFAP5 (reverse) CGAGTCCTTT
GGCTGCTGAATG; CDKN1C (forward) CGGACGAGA-
CAGGCGAACC, CDKN1C (reverse) GCGGCGGCTA
CCTGACTG; CRM1 (forward) CCACCTTGATTCG
TCCCCTCTC, CRM1 (reverse) ACCAACTGCTCCT
TCCTTCCTC; GAPDH (forward) CGCCAGCCGAGC-
CACATC, (reverse) AATCCGTTGACTCCGACCTT-
CAC; b-Actin (forward) AGCAAGCAGGAGTATGA
CGAGTC, b-Actin (reverse) AGAAAGGGTGTAACG-
CAACTAAGTC. Analysis was performed using the MyIQ
software program (Bio-Rad) and the fold changes were cal-
culated using either b-Actin or GAPDH as a reference
control as described earlier [49].
List of abbreviations
RNAP II: RNA polymerase II; Cdk9: Cyclin dependent kinase 9; NELF: Negative
elongation factor; DSIF: 5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole;
HEXIM1: hexamethylene bisacteamide-inducible 1.
Acknowledgements & Funding
The authors thank Dr. Dorothy E. Lewis, Baylor College of Medicine Flow
Cytometry core for help with cell sorting, and Baylor College of Medicine
Microarray core for DNA microarrays. This study was supported by NIH
grants AI35381 to A.P.R. and T32 AI7456 to R.R.
Author details
1Department of Molecular Virology & Microbiology, Baylor College of
Medicine, Houston, TX 77030, USA. 2Department of Pathology, University of
Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL
33136, USA.
Authors’ contributions
R.R. carried out experiments, analyzed the data and wrote the manuscript.
W.Y. constructed the shRNA vectors. A.P.R. conceived of the study and wrote
the paper. All authors read and approved the final manuscript.
Authors’ information
R.R. is a postdoctoral fellow and A.P.R. is Nancy Chang Professor in
Department of Molecular Virology & Microbiology, Baylor College of
Medicine, Houston, TX. W.Y. is currently a Resident in the Department of
Pathology, University of Miami Miller School of Medicine.
Competing interests
The authors declare that they have no competing interests.
Received: 12 April 2011 Accepted: 26 July 2011 Published: 26 July 2011
References
1. Peterlin BM, Price DH: Controlling the elongation phase of transcription
with P-TEFb. Mol Cell 2006, 23:297-305.
2. Zhou Q, Yik JH: The Yin and Yang of P-TEFb regulation: implications for
human immunodeficiency virus gene expression and global control of
cell growth and differentiation. Microbiol Mol Biol Rev 2006, 70:646-659.
3. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA: A chromatin
landmark and transcription initiation at most promoters in human cells.
Cell 2007, 130:77-88.
4. Hargreaves DC, Horng T, Medzhitov R: Control of inducible gene
expression by signal-dependent transcriptional elongation. Cell 2009,
138:129-145.
5. Michels AA, Bensaude O: RNA-driven cyclin-dependent kinase regulation:
when CDK9/cyclin T subunits of P-TEFb meet their ribonucleoprotein
partners. Biotechnol J 2008, 3:1022-1032.
6. Chen R, Yang Z, Zhou Q: Phosphorylated positive transcription
elongation factor b (P-TEFb) is tagged for inhibition through association
with 7SK snRNA. J Biol Chem 2004, 279:4153-4160.
7. Dow EC, Liu H, Rice AP: T-loop phosphorylated Cdk9 localizes to nuclear
speckle domains which may serve as sites of active P-TEFb function and
exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
J Cell Physiol 2010, 224:84-93.
8. Liou LY, Haaland RE, Herrmann CH, Rice AP: Cyclin T1 but not cyclin T2a is
induced by a post-transcriptional mechanism in PAMP-activated
monocyte-derived macrophages. J Leukoc Biol 2006, 79:388-396.
9. Sung TL, Rice AP: miR-198 inhibits HIV-1 gene expression and replication
in monocytes and its mechanism of action appears to involve
repression of cyclin T1. PLoS Pathog 2009, 5:e1000263.
10. Yu W, Wang Y, Shaw CA, Qin XF, Rice AP: Induction of the HIV-1 Tat co-
factor cyclin T1 during monocyte differentiation is required for the
regulated expression of a large portion of cellular mRNAs. Retrovirology
2006, 3:32.
11. Herrmann CH, Carroll RG, Wei P, Jones KA, Rice AP: Tat-associated kinase,
TAK, activity is regulated by distinct mechanisms in peripheral blood
lymphocytes and promonocytic cell lines. J Virol 1998, 72:9881-9888.
12. Sung TL, Rice AP: Effects of prostratin on Cyclin T1/P-TEFb function and
the gene expression profile in primary resting CD4+ T cells. Retrovirology
2006, 3:66.
13. Marshall RM, Salerno D, Garriga J, Grana X: Cyclin T1 expression is
regulated by multiple signaling pathways and mechanisms during
activation of human peripheral blood lymphocytes. J Immunol 2005,
175:6402-6411.
14. Yu W, Ramakrishnan R, Wang Y, Chiang K, Sung TL, Rice AP: Cyclin T1-
dependent genes in activated CD4 T and macrophage cell lines appear
enriched in HIV-1 co-factors. PLoS ONE 2008, 3:e3146.
15. Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, Maury W:
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and
flavopiridol correlates with release of free P-TEFb from the large,
inactive form of the complex. Retrovirology 2007, 4:47.
16. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM,
Peterlin BM, Price DH: Flavopiridol inhibits P-TEFb and blocks HIV-1
replication. J Biol Chem 2000, 275:28345-28348.
17. Chiu YL, Cao H, Jacque JM, Stevenson M, Rana TM: Inhibition of human
immunodeficiency virus type 1 replication by RNA interference directed
against human transcription elongation factor P-TEFb (CDK9/CyclinT1).
J Virol 2004, 78:2517-2529.
18. Flores O, Lee G, Kessler J, Miller M, Schlief W, Tomassini J, Hazuda D: Host-
cell positive transcription elongation factor b kinase activity is essential
and limiting for HIV type 1 replication. Proc Natl Acad Sci USA 1999,
96:7208-7213.
19. Foskett SM, Ghose R, Tang DN, Lewis DE, Rice AP: Antiapoptotic function
of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol 2001,
75:1220-1228.
20. Heredia A, Davis C, Bamba D, Le N, Gwarzo MY, Sadowska M, Gallo RC,
Redfield RR: Indirubin-3’-monoxime, a derivative of a Chinese
antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.
AIDS 2005, 19:2087-2095.
21. Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, Grana X: Direct
inhibition of CDK9 blocks HIV-1 replication without preventing T-cell
activation in primary human peripheral blood lymphocytes. Gene 2007,
405:65-78.
22. Chen R, Keating MJ, Gandhi V, Plunkett W: Transcription inhibition by
flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Blood 2005, 106:2513-2519.
23. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V,
Plunkett W: Mechanism of action of SNS-032, a novel cyclin-dependent
kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009,
113:4637-4645.
24. Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B,
Lee SK: Xylocydine, a novel Cdk inhibitor, is an effective inducer of
apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Cancer
Lett 2010, 287:196-206.
Ramakrishnan et al. BMC Research Notes 2011, 4:260
http://www.biomedcentral.com/1756-0500/4/260
Page 15 of 16
25. Lapenna S, Giordano A: Cell cycle kinases as therapeutic targets for
cancer. Nat Rev Drug Discov 2009, 8:547-566.
26. Liu H, Herrmann CH, Chiang K, Sung TL, Moon SH, Donehower LA, Rice AP:
55K isoform of CDK9 associates with Ku70 and is involved in DNA
repair. Biochem Biophys Res Commun 2010, 397:245-250.
27. Kohoutek J, Li Q, Blazek D, Luo Z, Jiang H, Peterlin BM: Cyclin T2 is
essential for mouse embryogenesis. Mol Cell Biol 2009, 29:3280-3285.
28. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A:
Rational siRNA design for RNA interference. Nat Biotechnol 2004,
22:326-330.
29. Peng J, Zhu Y, Milton JT, Price DH: Identification of multiple cyclin
subunits of human P-TEFb. Genes Dev 1998, 12:755-762.
30. Yao B, Rakhade SN, Li Q, Ahmed S, Krauss R, Draghici S, Loeb JA: Accuracy
of cDNA microarray methods to detect small gene expression changes
induced by neuregulin on breast epithelial cells. BMC Bioinformatics 2004,
5:99.
31. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC: Accuracy and
calibration of commercial oligonucleotide and custom cDNA
microarrays. Nucleic Acids Res 2002, 30:e48.
32. Bixler GV, Vanguilder HD, Brucklacher RM, Kimball SR, Bronson SK,
Freeman WM: Chronic insulin treatment of diabetes does not fully
normalize alterations in the retinal transcriptome. BMC Med Genomics
2011, 4:40.
33. VanGuilder HD, Bixler GV, Kutzler L, Brucklacher RM, Bronson SK, Kimball SR,
Freeman WM: Multi-modal proteomic analysis of retinal protein
expression alterations in a rat model of diabetic retinopathy. PLoS One
2011, 6:e16271.
34. Chao SH, Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA
polymerase II transcription in vivo. J Biol Chem 2001, 276:31793-31799.
35. De Luca A, De Falco M, Baldi A, Paggi MG: Cyclin T: three forms for
different roles in physiological and pathological functions. J Cell Physiol
2003, 194:101-107.
36. Giacinti C, Bagella L, Puri PL, Giordano A, Simone C: MyoD recruits the
cdk9/cyclin T2 complex on myogenic-genes regulatory regions. J Cell
Physiol 2006, 206:807-813.
37. Shim EY, Walker AK, Shi Y, Blackwell TK: CDK-9/cyclin T (P-TEFb) is
required in two postinitiation pathways for transcription in the
C. elegans embryo. Genes Dev 2002, 16:2135-2146.
38. Liou LY, Herrmann CH, Rice AP: Transient induction of cyclin T1 during
human macrophage differentiation regulates human immunodeficiency
virus type 1 Tat transactivation function. J Virol 2002, 76:10579-10587.
39. Rice AP, Herrmann CH: Regulation of TAK/P-TEFb in CD4+ T lymphocytes
and macrophages. Curr HIV Res 2003, 1:395-404.
40. Lin X, Taube R, Fujinaga K, Peterlin BM: P-TEFb containing cyclin K and
Cdk9 can activate transcription via RNA. J Biol Chem 2002,
277:16873-16878.
41. Yu DS, Cortez D: A role for cdk9-cyclin k in maintaining genome
integrity. Cell Cycle 2011, 10:28-32.
42. Garriga J, Xie H, Obradovic Z, Grana X: Selective control of gene
expression by CDK9 in human cells. J Cell Physiol 2010, 222:200-208.
43. Yang X, Herrmann CH, Rice AP: The human immunodeficiency virus Tat
proteins specifically associate with TAK in vivo and require the carboxyl-
terminal domain of RNA polymerase II for function. J Virol 1996,
70:4576-4584.
44. Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T
cells by lentiviral-mediated delivery of small interfering RNA against
CCR5. Proc Natl Acad Sci USA 2003, 100:183-188.
45. Qin LX, Beyer RP, Hudson FN, Linford NJ, Morris DE, Kerr KF: Evaluation of
methods for oligonucleotide array data via quantitative real-time PCR.
BMC Bioinformatics 2006, 7:23.
46. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR:
MAPPFinder: using Gene Ontology and GenMAPP to create a global
gene-expression profile from microarray data. Genome Biol 2003, 4:R7.
47. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA:
DAVID: Database for Annotation, Visualization, and Integrated Discovery.
Genome Biol 2003, 4:P3.
48. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009, 4:44-57.
49. Haaland RE, Herrmann CH, Rice AP: siRNA depletion of 7SK snRNA
induces apoptosis but does not affect expression of the HIV-1 LTR or
P-TEFb-dependent cellular genes. J Cell Physiol 2005, 205:463-470.
doi:10.1186/1756-0500-4-260
Cite this article as: Ramakrishnan et al.: Limited redundancy in genes
regulated by Cyclin T2 and Cyclin T1. BMC Research Notes 2011 4:260.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ramakrishnan et al. BMC Research Notes 2011, 4:260
http://www.biomedcentral.com/1756-0500/4/260
Page 16 of 16
